From Morphological Imaging to Molecular Targeting: Implications to Preclinical DevelopmentMarkus Schwaiger, Ludger Dinkelborg, Hermann Schweinfurth Springer Science & Business Media, 2004 M06 16 - 196 pages Because of the current progress in molecular medicine (genomics, proteomics), a plethora of new and often human-specific targets are being identified. These targets often play a significant role in the pathogenesis of diseases, and identifying them offers the potential for early diagnosis and intervention. An early in vivo validation of specific ligands binding to these targets in humans is needed to as- sess their potential for targeted imaging and radiotherapy. Further- VI Preface more, such validation studies may allow for a better understanding of the molecular processes underlying phannacologic activity and therefore for a more successful development of phannaceuticals in general. The purpose of the Ernst Schering Research Foundation (ESRF) Workshop 48 was to provide a forum for an open exchange on the state of the art in the early development of such radiophanna- ceuticals. Experts from academia, industry, and regulatory authori- ties were invited to give presentations on aspects covering the identi- fication of targets, preclinical studies on the safety of ligands, as well as their validation in human clinical trials. It was our intention to cover both the opportunities and the challenges that scientists in this field are facing. Radiopharmaceuticals are uniquely suitable for the above-men- tioned target validation studies. |
Contents
R Solari | 20 |
Target Discovery and Validation | 27 |
Noninvasive Imaging in Drug Discovery and Development | 47 |
Internal Dose Assessment | 77 |
PET for Drug Development | 95 |
Future Directions in Molecular Imaging | 131 |
The Japanese Perspective on Radiopharmaceuticals | 167 |
The pharmaceutical industry as we know it is still relatively young | 183 |
Other editions - View all
Common terms and phrases
absorbed dose Acad Sci USA activity analysis animal antibody antisense apoptosis assays assessment binding biodistribution Biol biological brain cells clinical trials compounds CPMP detection disease dosimetry drug development drug discovery drug target effects enzymes evaluation fluorescent function Gambhir SS gene expression gene therapy genetic genome genotoxicity guidance Haberkorn herpes simplex virus human identify imaging approaches Japan kinetic labeled ligand metabolic methods mice microdose molecular imaging molecules monitoring mouse mRNA Natl Acad Sci nonclinical studies Noninvasive Nucl oligonucleotides optical imaging organs pathway peptide pharmaceutical pharmacokinetics pharmacological phenotype positron emission tomography potential preclinical probes Proc Natl Acad protein proteomics quantitative radioactivity radiodiagnostic radiolabeled radioligand radionuclide radiopharmaceuticals radiotherapeutic receptor regulatory reporter gene Rudin safety studies Schwaiger sequence single-dose specific target validation techniques therapeutic thymidine kinase tion tissue toxicity studies tracer transfected transgenic transport treatment tumor uptake visualization vitro vivo Weissleder yeast